The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with reassurance, ...

June 18, 2010 (UPDATED June 21, 2010) — The US Food and Drug Administration (FDA) has approved a single-capsule formulation of 0.5-mg dutasteride and 0.4-mg tamsulosin (Jalyn; GlaxoSmithKline) for ...

Advances in healthcare and preventive medicine are markedly improving both life expectancy and overall quality of life (QOL) in the aging male population of developed countries. The term "successful ...

An enlarged prostate—also known as benign prostatic hyperplasia (BPH)—is a natural sign of aging that affects half of all men over the age of 40. The good news is this condition does not increase your ...

An enlarged prostate is a condition that most commonly affects men over 50, but it can begin once you reach your 30s. This condition, often called benign prostatic hyperplasia or BPH, is non-cancerous ...

Men pharmacologically treated for benign prostatic hyperplasia (BPH) experienced significant improvements in overactive bladder (OAB) symptoms after treatment with vibegron (Gemtesa), according to ...

For a topic that people mostly avoid bringing up in casual conversation, incontinence represents a huge addressable market.